Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01231971 · ClinicalTrials.gov registry record

Alzheimer's Disease Neuroimaging Initiative 2

A clinical trial of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), sponsored by University of Southern California.

Completed
Registry status
1,182
Enrollment target
20
Study locations

NCT01231971 is a study of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) that has completed, run by University of Southern California. The registered enrollment target is 1,182 participants, above the 97-participant average among 19 other Mild Cognitive Impairment (MCI) trials with a reported enrollment target (1119% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01231971, a study of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD), has completed, sponsored by University of Southern California.

COMPLETED
Registry status
1,182 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American Recovery and Reinvestment Act), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI2 seeks to inform the neuroscience of AD. This information will aid in the early detection of AD, and in measuring the effectiveness of treatments in future clinical trials.

Conditions Studied

Mild Cognitive Impairment (MCI) Alzheimer's Disease (AD) Significant Memory Concern (SMC) Early Mild Cognitive Impairment (EMCI) Late Mild Cognitive Impairment (LMCI)

Interventions

  • DRUG Flortaucipir
  • DRUG Florbetapir

Study Locations (20)

California

  • University of California, Irvine - Irvine
  • University of California, San Diego - La Jolla
  • University of Southern California - Los Angeles
  • University of California, Los Angeles - Los Angeles
  • University of California, Davis - Martinez
  • University of California, Irvine (Brain Imaging Center) - Orange
  • Stanford University / PAIRE - Palo Alto
  • University of California, San Francisco - San Francisco

Florida

  • Mayo Clinic, Jacksonville - Jacksonville
  • Wien Center for Clinical Research - Miami Beach
  • USF Health Byrd Alzheimer's Institute - Tampa
  • Premiere Research Institute - West Palm Beach

Arizona

  • Banner Alzheimer's Institute - Phoenix
  • Banner Sun Health Research Institute - Sun City

District of Columbia

  • Georgetown University - Washington D.C.
  • Howard University - Washington D.C.

Alabama

  • University of Alabama, Birmingham - Birmingham

Connecticut

  • Yale University School of Medicine - New Haven

Georgia

  • Emory University - Atlanta

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 1,182 participants
Start Date 2011-02-14
Est. Completion 2017-11-29

Sponsor

University of Southern California

617 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01231971

The ClinicalTrials.gov registry entry for NCT01231971 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,182 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 97-participant average among 19 other Mild Cognitive Impairment (MCI) trials with a reported enrollment target (1119% higher). The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Mild Cognitive Impairment (MCI) appearing as the primary indexed condition, and to 2 interventions - of which Flortaucipir is the first listed.

NCT01231971 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT01231971 about?

NCT01231971 is a clinical study titled "Alzheimer's Disease Neuroimaging Initiative 2". The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1) and ADNI-GO (Grand Opportunity; a study funded through an NIH grant under the American Recovery and Reinvestment Act), to examine how brain imaging technology can b...

What is the current status of trial NCT01231971?

This trial is currently completed. The enrollment target is 1,182 participants. The study started on 2011-02-14. Estimated completion is 2017-11-29.

What conditions does trial NCT01231971 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI).

What interventions are being tested in trial NCT01231971?

The interventions under investigation include: Flortaucipir (DRUG), Florbetapir (DRUG).

Who is sponsoring clinical trial NCT01231971?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01231971 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mild Cognitive Impairment (MCI)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mild Cognitive Impairment (MCI)

All registered trials for this condition

Alzheimer's Disease (AD)

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.